Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 1, 2006

View Archived Issues

Q1 developments at Ono

sanofi-aventis: H1 review

New KCa channel activator a promising strategy for micturition control

Novel treatment options for metabolic disorders described in recent patents

sanofi-aventis patents novel cannabinoid CB1 receptor antagonists

New strategies for treatment of glaucoma reported in recent patents

New anxiolytics disclosed in a recent Ono patent

Alzheimer's disease candidate AL-108 begins phase Ib study

Phase II study of GV-1001 in hepatocellular carcinoma cleared to begin in France

Obesity drug candidate BVT-74316 enters phase I testing

Positive phase I results for universal allergy immunotherapy RP-01

Enrollment completed in iloperidone and VEC-162 phase III trials

MLN-0415 studied in phase I for inflammatory disorders

SBIR grant to support Velcura's research into processes in bone formation

Novel delta opioid agonist ADL-5859 begins phase I study

ChemDiv and Yale receive NIH grant for adrenal gland disorder research

Roche discontinues codevelopment of daclizumab in asthma

New preclinical data for shingles compound FV-100

Genzyme to initiate tender offer for AnorMED

MolecularMD to support phase II study of Ablvax

MediGene to acquire Avidex

PR-104, a hypoxia-activated prodrug under clinical development for cancer

Bristol-Myers Squibb report on new potent and selective FXa inhibitor

GSK reports on SB-737050A, their new targeted lead candidate for schizophrenia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...